Overview

Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the response rate of capecitabine and irinotecan combination therapy in patients with metastatic breast cancer
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Center, Korea
Treatments:
Camptothecin
Capecitabine
Irinotecan
Taxane